By Denny Jacob
Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line.
The biotechnology pioneer on Wednesday said it logged net income of $266.8 million, or $1.83 a share, compared to $249.7 million, or $1.71 a share, a year earlier.
Stripping out certain one-time items, earnings came in at $3.44 a share. Analysts polled by FactSet expected $3.35 a share in adjusted earnings.
Revenue rose to $2.45 billion from $2.39 billion. Analysts expected $2.41 billion.
Biogen said revenue from product launches continued to offset year-over-year declines in multiple-sclerosis product revenue.
The Cambridge, Mass., company forecast revenue in 2025 to decline by a mid-single-digit percentage at constant currency compared with 2024. Biogen also guided for full-year adjusted earnings per share of between $15.25 and $16.25; analysts expected $16.33 a share in adjusted earnings.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 12, 2025 07:23 ET (12:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.